Helping Patients Find Posaconazole: A Provider's Toolkit

When patients on Posaconazole (Noxafil) report difficulty filling their prescriptions, providers play a critical role in bridging the gap between drug availability and patient access. This guide offers practical, actionable strategies for helping your patients locate Posaconazole during supply disruptions.

Understanding the Current Supply Landscape

As of 2026, the Posaconazole supply situation involves several key dynamics:

• The original immediate-release oral suspension was discontinued in 2024, eliminating the primary liquid formulation option
• Generic delayed-release tablets (100 mg) are the most widely available formulation, produced by multiple manufacturers
• The Noxafil PowderMix delayed-release oral suspension serves as the replacement liquid formulation
• The IV formulation remains available for inpatient use
• Spot shortages of oral formulations occur intermittently due to limited manufacturer base and specialty distribution

For a comprehensive clinical overview of the shortage, see: Posaconazole Shortage: What Providers and Prescribers Need to Know in 2026.

Step 1: Identify At-Risk Patients Proactively

Don't wait for patients to report problems. Proactively identify patients who may be affected:

• Review active prescriptions: Generate a list of patients currently on Posaconazole from your EHR
• Flag patients on the discontinued IR suspension: If any patients still have active orders for the IR oral suspension, update their prescriptions to an available formulation
• Assess refill timing: Identify patients whose refills are due within the next 2–4 weeks and confirm pharmacy availability
• Prioritize highest-risk patients: Patients with active neutropenia, recent HSCT, or severe GVHD are at greatest risk if prophylaxis is interrupted

Step 2: Use Real-Time Pharmacy Availability Tools

MedFinder for Providers allows you to check which pharmacies near your patient currently have Posaconazole in stock. This eliminates the time-consuming process of calling individual pharmacies.

How to use MedFinder in your workflow:

1. Navigate to medfinder.com/providers
2. Search for Posaconazole by name
3. Enter your patient's ZIP code or city
4. Review the list of pharmacies with confirmed stock
5. Send the prescription to a pharmacy with availability, or share the results with your patient

Integrating this step into your prescribing workflow can prevent prescription delays before they happen.

Step 3: Leverage Specialty Pharmacy Networks

Specialty pharmacies are the most reliable source for Posaconazole. Key specialty pharmacy networks that commonly stock Posaconazole include:

• CVS Specialty
• Accredo (Express Scripts)
• Optum Specialty Pharmacy
• AllianceRx Walgreens
• Amber Specialty Pharmacy
• Hospital-affiliated outpatient pharmacies

Provider action items:

• Identify which specialty pharmacy your patient's insurance plan requires or prefers
• Establish prescriber accounts with major specialty pharmacies to streamline prescription transfers
• Keep specialty pharmacy contact numbers readily available for your clinical team

Step 4: Manage Formulation Transitions

If your patient needs to switch formulations due to availability, key clinical considerations include:

Switching from IR Suspension to Delayed-Release Tablets

• Delayed-release tablets: 300 mg (three 100 mg tablets) twice daily on Day 1, then 300 mg once daily
• Tablets must be swallowed whole with food; cannot be crushed, split, or chewed
• Not appropriate for patients with significant dysphagia or severe mucositis
• Obtain a trough level 5–7 days after the switch to confirm adequate drug exposure

Switching to PowderMix Delayed-Release Oral Suspension

• Follows the same dosing regimen as delayed-release tablets (300 mg loading, then 300 mg once daily)
• Appropriate for patients who cannot swallow tablets
• Not dose-equivalent to the discontinued IR suspension — do not use old IR suspension dosing
• Obtain a trough level after initiation to confirm therapeutic concentrations

Switching from IV to Oral

• Transition to oral when clinically appropriate, typically when the patient can tolerate oral intake
• Confirm outpatient pharmacy has oral Posaconazole in stock before discharge
• Consider a brief overlap period (one dose of oral before stopping IV) to maintain therapeutic levels

Step 5: Navigate Insurance and Prior Authorization

Insurance barriers are a common source of delay for Posaconazole prescriptions. Strategies to streamline the process:

• Submit prior authorization proactively: Don't wait until the patient arrives at the pharmacy. Initiate PA as soon as Posaconazole is prescribed.
• Document medical necessity clearly: Include the specific indication (e.g., antifungal prophylaxis during induction chemotherapy for AML), relevant ICD-10 codes, and supporting guideline references (IDSA, NCCN, ECIL).
• Appeal denials promptly: If the initial PA is denied, request a peer-to-peer review with the insurance company's medical director. Emphasize the evidence base for Posaconazole prophylaxis in the specific patient population.
• Consider specialty pharmacy PA services: Many specialty pharmacies have dedicated teams that handle prior authorizations on behalf of prescribers.

Step 6: Connect Patients with Financial Assistance

Even when Posaconazole is in stock, cost can prevent patients from filling their prescriptions. Provider-accessible resources include:

• Merck Patient Assistance Program (merckhelps.com): Free Noxafil for eligible uninsured or underinsured patients
• GoodRx / SingleCare coupons: Can reduce generic Posaconazole to approximately $187–$250 for 90 tablets versus $3,600+ cash price
• Patient Access Network (PAN) Foundation: May offer copay assistance for eligible patients
• Social work referrals: Hospital social workers can identify additional local and national assistance programs

For a comprehensive overview, see: How to Help Patients Save Money on Posaconazole: A Provider's Guide.

Step 7: Prepare Alternative Regimens

Have evidence-based alternative regimens ready for situations when Posaconazole is truly unavailable:

• Primary alternative for broad-spectrum coverage: Isavuconazonium (Cresemba) — covers Aspergillus and Mucorales
• Primary alternative for Aspergillus coverage: Voriconazole — FDA-approved for treatment, used off-label for prophylaxis
• Budget-conscious alternative: Itraconazole — inferior to Posaconazole for prophylaxis per randomized trial data, but better than no coverage
• Inpatient bridge: Liposomal amphotericin B (AmBisome) for patients who cannot tolerate any oral azole

Document the rationale for alternative selection and plan for re-evaluation when Posaconazole becomes available.

Workflow Summary: Quick Reference

1. ✅ Proactively identify patients on Posaconazole
2. ✅ Check stock using MedFinder for Providers
3. ✅ Route prescriptions to specialty pharmacies
4. ✅ Update formulations and dosing as needed
5. ✅ Submit prior authorizations proactively
6. ✅ Connect patients with financial assistance
7. ✅ Have alternative regimens documented and ready
8. ✅ Monitor trough levels during transitions

Summary

Providers are uniquely positioned to prevent treatment disruptions for patients who depend on Posaconazole. By proactively monitoring supply, leveraging real-time availability tools like MedFinder, coordinating with specialty pharmacies, and having backup plans in place, you can ensure your patients maintain the antifungal protection they need — even during supply disruptions.